Equities

Harvard Apparatus Regenerative Technology Inc

HRGN:QBB

Harvard Apparatus Regenerative Technology Inc

Actions
  • Price (USD)2.46
  • Today's Change0.02 / 0.82%
  • Shares traded100.00
  • 1 Year change--
  • Beta-1.4071
Data delayed at least 15 minutes, as of May 03 2024 14:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma, or birth defects. The Company is targeting the conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy and birth defects. Its additional product candidates in its development pipeline are targeted at the reconstruction of the colon and uterus wound repair. Its product candidate includes Cellspan Esophageal Implant, and Cellspan Bronchial Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection.

  • Revenue in USD (TTM)103.00k
  • Net income in USD-9.02m
  • Incorporated2012
  • Employees10.00
  • Location
    Harvard Apparatus Regenerative Technology Inc84 October Hill Road, Suite 11HOLLISTON 01746United StatesUSA
  • Phone+1 (774) 233-7300
  • Fax+1 (774) 233-7302
  • Websitehttps://www.biostage.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Positron Corp1.24m-1.27m27.32m22.00------22.09-0.0897-0.08970.0876-0.11090.59762.296.56---61.35-224.13----32.989.85-102.67-201.870.0638-------10.060.275163.63--4.36--
BioRegenx Inc22.24k-571.17k29.75m10.00------1,337.73-0.0021-0.00210.00008-0.00080.4899----2,224.00-1,258.22------96.85---2,568.21-----13.2366.29---47.25---629.37------
Neuroone Medical Technologies Corp2.86m-13.47m31.38m16.00--6.80--10.99-0.6922-0.69220.14240.17790.3691.668.94178,516.30-174.02-172.88-211.08-274.7427.16---471.65-674.972.52--0.00--62.66---18.60------
T2 Biosystems Inc7.19m-50.08m32.09m113.00------4.46-147.02-147.023.58-6.910.20813.384.0263,654.87-144.89-106.01-3,521.59-253.03-113.58-12.60-696.19-317.930.3628--3.12---67.75-7.2919.66---20.19--
Akili Inc1.68m-59.49m32.13m68.00--0.5473--19.15-0.761-0.7610.02150.7470.0149--9.8424,676.47-52.90---59.98--51.19---3,545.47-----27.180.1817--419.50---212.48------
Retractable Technologies Inc43.60m-7.24m32.51m148.00--0.3282114.400.7458-0.242-0.2421.463.320.23231.805.62294,573.80-3.7412.45-3.9614.5120.8940.82-16.0818.096.41-3.150.0153---54.025.55-249.46--17.42--
Precision Optics Corporation Inc19.22m-1.72m33.68m84.00--2.98--1.75-0.289-0.2893.271.871.094.315.09228,782.90-9.77-6.71-13.54-10.5533.3533.65-8.94-5.021.10-10.390.1823--34.2339.1284.42--19.39--
Inspira Technologies Oxy BHN Ltd0.00-11.29m34.24m37.00--5.40-----0.9549-0.95490.000.36660.00----0.00-88.60-114.98-108.36-159.56------------0.00------24.64------
Harvard Apparatus Regenertv Tchnlgy Inc103.00k-9.02m34.93m10.00--20.68--339.11-0.6801-0.68010.00770.1180.0411----10,300.00-356.80-330.30-666.79-1,524.8876.70---8,684.47-35,138.840.7572--0.00-------44.28---39.07--
LENSAR Inc42.16m-14.38m35.55m130.00--1.06--0.8432-1.34-1.343.774.160.67231.547.65324,338.50-22.93-30.97-28.10-36.9450.0651.04-34.11-52.302.64--0.00--19.2511.5727.77---42.91--
SeaStar Medical Holding Corp0.00-26.23m36.71m12.00---------1.28-1.280.00-0.29130.00----0.00-800.85-----------------26.51---------115.19------
electroCore, Inc.16.03m-18.83m36.74m68.00--4.94--2.29-3.56-3.562.911.240.78471.3528.68235,735.30-92.19-70.73-146.63-88.9682.5175.81-117.49-352.821.49--0.00--86.5774.4215.02---5.88--
Co-Diagnostics Inc6.81m-35.33m37.51m155.00--0.4361--5.51-1.20-1.200.23212.750.06241.203.6343,948.71-32.365.77-33.856.1538.5782.24-518.6810.9410.52--0.000.00-80.09179.54-148.15--101.27--
iCAD Inc17.32m-7.01m39.54m67.00--1.18--2.28-0.2742-0.19250.67471.270.37190.80342.16258,477.60-15.06-23.94-19.23-34.1485.3776.96-40.48-45.024.26--0.00---12.54-7.5329.32--23.88--
Nutriband Inc2.09m-5.28m40.04m13.00--5.01--19.17-0.6738-0.67380.26640.72910.21767.1216.70---55.06-60.48-59.75-74.6638.8027.55-253.02-388.142.54-142.450.2792--46.23--29.65------
Data as of May 03 2024. Currency figures normalised to Harvard Apparatus Regenerative Technology Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.